Results 21 to 30 of about 18,668,916 (320)

Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes

Thrombosis Journal, 2023
Background Anti-factor Xa assays and activated partial thromboplastin time (aPTT) are mainly employed to monitor patients treated with heparins. According to the Clinical and Laboratory Standards Institute and the French Working Group on Haemostasis and ...
Marion Gremillet, Laurie Talon, Aurélien Lebreton, Thomas Sinegre   +3 more
doaj   +1 more source

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Journal of Clinical Oncology, 2018
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients.
A. Young, A. Marshall, Jenny Thirlwall, O. Chapman, A. Lokare, C. Hill, Danielle Hale, J. Dunn, G. Lyman, Charles E. Hutchinson, P. Maccallum, Ajay Kakkar, F. Hobbs, S. Petrou, J. Dale, C. Poole, A. Maraveyas, M. Levine   +17 more
semanticscholar   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells

Haematologica, 2014
Vitamin K-dependent proteases generated in response to vascular injury and infection enable fibrin clot formation, but also trigger distinct immuno-regulatory signaling pathways on myeloid cells.
Eimear M. Gleeson, James S. O’Donnell, Emily Hams, Fionnuala Ní Áinle, Bridget-Ann Kenny, Padraic G. Fallon, Roger J.S. Preston   +6 more
doaj   +1 more source

Assessing Anticoagulation in Neonates With Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Does Anti-Factor Xa or Thromboelastometry Provide Additional Benefit?

Frontiers in Pediatrics, 2021
Objective: The optimal management of anticoagulation in neonatal/pediatric patients during extracorporeal membrane oxygenation (ECMO) has not been established yet and varies greatly among ECMO centers worldwide.
Alba Perez Ortiz, Carl E. Dempfle, Toni Jung, Thalia Doniga, Christel Weiß, Svetlana Hetjens, Thomas Schaible, Neysan Rafat   +7 more
doaj   +1 more source

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine, 2019
Background Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa ...
S. Connolly, M. Crowther, J. Eikelboom, C. M. Gibson, J. Curnutte, J. Lawrence, Patrick Yue, M. Bronson, Gen-Min Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, A. Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, A. Demchuk, D. Pallin, M. Concha, S. Goodman, J. Leeds, Sonia Souza, D. Siegal, E. Zotova, Brandi Meeks, S. Ahmad, J. Nakamya, T. Milling   +28 more
semanticscholar   +1 more source

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Research and Practice in Thrombosis and Haemostasis, 2021
Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp   +18 more
doaj   +1 more source

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine, 2016
BACKGROUND Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.
Stuart J Connolly, T. Milling, J. Eikelboom, C. M. Gibson, J. Curnutte, A. Gold, M. Bronson, Gen-Min Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, Alexander T Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, S. Goodman, J. Leeds, Brian L. Wiens, Deborah M. Siegal, E. Zotova, Brandi Meeks, J. Nakamya, Ting W. Lim, M. Crowther   +24 more
semanticscholar   +1 more source

The role of factor Xa inhibitors in venous thromboembolism treatment [PDF]

, 2015
Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Ansell, J. E., Cabral KP, Cabral, K. P., Ansell JE   +3 more
core   +1 more source

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source